Sunshine Novo and Anlong Biotechnology have officially reached a project and strategic cooperation to jointly promote the application of small nucleic acid siRNA technology platform in the field of cardiovascular and cerebrovascular treatment, and develop an innovative small nucleic acid (siRNA) drug in this field. This collaboration will leverage the unique advantages of siRNA technology to address pain points in current disease treatments, provide patients with longer lasting and more convenient treatment options, and promote innovation and development of small nucleic acid drugs in the field of cardiovascular and cerebrovascular chronic disease treatment.

Breakthrough advantages of siRNA technology

SiRNA technology, as an emerging therapeutic approach, has shown great potential in the field of chronic disease treatment in recent years. SiRNA drugs achieve long-lasting treatment by targeting specific mRNA molecules and inhibiting the expression of disease-related proteins. Compared with traditional daily medication, siRNA drugs can be administered quarterly or semi annually, greatly improving patient compliance.

The rapid growth of siRNA market

With the continuous launch of siRNA drugs, the global siRNA market has rapidly grown from $13 million in 2018 to $1.597 billion in 2023, and is expected to reach $12.8 billion by 2030.

Vision for cooperation between both parties

Sunshine Novo and Anlong Biotechnology will combine their advantages in siRNA technology research and commercialization to jointly promote the application of siRNA technology in the treatment of cardiovascular and cerebrovascular chronic diseases. By developing long-lasting and efficient siRNA drugs, both parties hope to solve the problems of poor compliance in current disease treatment and provide patients with better targeted and precise treatment options.

This cooperation is expected to not only promote breakthroughs in siRNA technology in related therapeutic fields, but also provide new ideas for the treatment of other chronic diseases. With the continuous maturity and increasing market acceptance of siRNA technology, it is expected to be widely applied in more chronic disease fields in the future.

Future prospects

The cooperation between Sunshine Novo and Anlong Biotechnology marks the acceleration of China's innovation in siRNA technology. Through this collaboration, Sunshine Novo and Anlong Biotech will not only provide more long-term and convenient treatment solutions for cardiovascular and cerebrovascular patients, but also inject new vitality into the field of chronic disease treatment, promoting the entire industry to develop in a more efficient and precise direction.

About Anlong Biotechnology

Anlong Biotech is a biopharmaceutical company focused on gene therapy and RNA technology innovation, dedicated to developing innovative drugs based on cutting-edge technologies such as siRNA (small interfering RNA) and mRNA. The company aims to address unmet clinical needs and focuses on the treatment of chronic diseases, rare diseases, and tumors. Anlong Biotechnology has an advanced RNA technology platform and a strong R&D team, which gives it significant advantages in the design, development, and commercialization of siRNA drugs. Through cooperation with domestic and foreign research institutions and enterprises, Anlong Biotechnology is accelerating the clinical research of multiple innovative drugs, aiming to provide more efficient and long-lasting treatment options for patients worldwide. The company is driven by innovation and committed to becoming a leading enterprise in the field of RNA technology, promoting the progress of the biopharmaceutical industry.